Industry News

Biotechnology Industry News

AstraZeneca isn’t letting a…

March 27th, 2026|FierceBiotech|

AstraZeneca isn’t letting a death in a China trial detract from the potential of its $1 billion in vivo bet, even as the candidate’s safety and efficacy profile have so far failed to separate it

Otsuka Pharmaceutical has acquired…

March 27th, 2026|FierceBiotech|

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its wholly owned subsidiary, Otsuka America, in a deal that could also deliver up to $525 million in milestone payments tied to assets in

Takeda has posted phase 3 data on…

March 27th, 2026|FierceBiotech|

Takeda has posted phase 3 data on an autoimmune asset it acquired for $4 billion, laying down a marker ahead of a fight for market share with companies including Bristol Myers Squibb and Johnson &

Merck & Co. has lifted the lid…

March 27th, 2026|FierceBiotech|

Merck & Co. has lifted the lid on the third successful phase 3 trial of its PCSK9 inhibitor, showing the edge the cardiovascular disease prospect has over other oral non-statin therapies.

AstraZeneca’s chronic…

March 27th, 2026|FierceBiotech|

AstraZeneca’s chronic obstructive pulmonary disease drug candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and Sanofi.

Seasoned biotech takeover titan…

March 26th, 2026|FierceBiotech|

Seasoned biotech takeover titan Kevin Tang has struck again. After serving as board chair of Aurinia since 2024, Tang has now ascended to the CEO spot and swapped out the company’s C-suite with a cadre

Oral peptide specialist Pinnacle…

March 26th, 2026|FierceBiotech|

Oral peptide specialist Pinnacle Medicines has secured an $89 million series B with backing from investors in the U.S. and China, bringing the company’s total fundraising haul to $134 million.

John Stanford spent a busy day on…

March 26th, 2026|FierceBiotech|

John Stanford spent a busy day on Capitol Hill this week making the case that the success of the domestic biotech industry is an issue of national security, health care access and economic competitiveness.

Wave Life Sciences linked its…

March 26th, 2026|FierceBiotech|

Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive the stock down by more than 50% despite the biotech hailing the data

Biopharma funding fell 20% last…

March 26th, 2026|FierceBiotech|

Biopharma funding fell 20% last year, reversing the post-pandemic recovery as the IPO haul dropped to the lowest level of the past 10 years, according to an IQVIA analysis.

Radioligand therapy has…

March 25th, 2026|FierceBiotech|

Radioligand therapy has irrevocably changed oncology, proving we can map biology and strike cancer cells with unprecedented precision. Research suggests that up to 80% of cancers could potentially be addressed by this approach.

Maze Therapeutics has revealed…

March 25th, 2026|FierceBiotech|

Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” But many investors were racing for the exits Wednesday.

Sarepta Therapeutics has shared…

March 25th, 2026|FierceBiotech|

Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its decision to bet big on Arrowhead Pharmaceuticals’ pipeline.

Full 12-month data from Ocugen’s…

March 24th, 2026|FierceBiotech|

Full 12-month data from Ocugen’s phase 2 eye disease gene therapy show the therapy significantly reduces the size of lesions, though the treatment’s smaller effect compared to an earlier preliminary analysis sent the biotech’s stock